The Role of the Immune Response in Controlling the Size of the HIV Reservoir.

免疫反应在控制艾滋病病毒库大小中的作用。

基本信息

  • 批准号:
    8333947
  • 负责人:
  • 金额:
    $ 19.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-20 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): HIV-infected individuals accumulate a reservoir of treatment-resistant, latently infected resting CD4+ T cells. A special category of HIV infected individuals called elite suppressors have undetectable viral loads in the absence of highly active antiretroviral therapy (HAART) and have a smaller HIV reservoir. There is compelling evidence that elite suppressors (ES) have higher functioning CTL activity against HIV than treated and untreated chronic progressors. Our recent data provide evidence that CTL in ES have activity against latently infected resting CD4+ T cells in vivo. Specifically, we demonstrate for the first time that ES patients have dramatically lower levels of integrated HIV DNA and a relatively large excess of unintegrated HIV DNA compared to HAART patients. This is consistent with CTL pressure since HIV proteins are expressed more efficiently from integrated compared to unintegrated HIV DNA. In addition, we have preliminary data that latently infected resting CD4+ T cells express HIV proteins but do not permit spreading infection and thus should be susceptible to CTL pressure. At the same time, we show with our in vitro model of latency that CTL have activity against latently infected resting CD4+ T cells. Thus, the range of CTL targets is greater than previously thought since it appears that latently infected cells can be targets of CTL. In this application, we plan to test for further evidence of CTL pressure by assessing the frequency of HIV RNA+ cells among resting CD4+ T cells in ES vs HAART patients. We expect the frequency of HIV RNA+ cells normalized to integration to be lower in ES because we expect the majority of HIV RNA+ cells will express protein and be subjected to CTL lysis. Finally, we will determine if integration levels increase over time (as suggested by our preliminary data) in all or a subset of ES and if an increase in integration levels correlates with a loss of CTL function in ES. We also consider the alternate hypothesis that integration levels may increase over time in ES because defective proviruses accumulate.
描述(由申请人提供):hiv感染的个体积累了一个治疗耐药的、潜伏感染的静息CD4+ T细胞库。在缺乏高效抗逆转录病毒治疗(HAART)的情况下,被称为精英抑制者的一类特殊HIV感染者的病毒载量无法检测,并且具有较小的HIV库。有令人信服的证据表明,精英抑制者(ES)比治疗和未治疗的慢性进展者具有更高的抗HIV功能CTL活性。我们最近的数据提供了证据,证明ES中的CTL在体内对潜伏感染的静止CD4+ T细胞具有活性。具体来说,我们首次证明,与HAART患者相比,ES患者的整合HIV DNA水平显著降低,而非整合HIV DNA水平相对较高。这与CTL压力是一致的,因为与未整合的HIV DNA相比,整合的HIV蛋白表达效率更高。此外,我们有初步数据表明,潜伏感染的静止CD4+ T细胞表达HIV蛋白,但不允许传播感染,因此应该对CTL压力敏感。同时,我们通过体外潜伏期模型证明CTL对潜伏感染的静止CD4+ T细胞具有活性。因此,CTL靶点的范围比以前认为的要大,因为潜伏感染的细胞似乎可以成为CTL的靶点。在这项应用中,我们计划通过评估ES与HAART患者静息CD4+ T细胞中HIV RNA+细胞的频率来检测CTL压力的进一步证据。我们预计在ES中,HIV RNA+细胞归一化为整合的频率较低,因为我们预计大多数HIV RNA+细胞将表达蛋白质并受到CTL裂解。最后,我们将确定在ES的所有或一个子集中整合水平是否随着时间的推移而增加(正如我们的初步数据所表明的那样),以及整合水平的增加是否与ES中CTL功能的丧失相关。我们还考虑了另一种假设,即ES的整合水平可能随着时间的推移而增加,因为有缺陷的原病毒会积累。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Una T O'Doherty其他文献

Una T O'Doherty的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Una T O'Doherty', 18)}}的其他基金

The barcode project: a strategy to track the early naïve reservoir
条形码项目:追踪早期幼稚水库的策略
  • 批准号:
    10762820
  • 财政年份:
    2023
  • 资助金额:
    $ 19.07万
  • 项目类别:
Determinants of reservoir contraction and expansion in vivo, ex vivo, and in vitro
体内、离体和体外储库收缩和扩张的决定因素
  • 批准号:
    10358573
  • 财政年份:
    2020
  • 资助金额:
    $ 19.07万
  • 项目类别:
Determinants of reservoir contraction and expansion in vivo, ex vivo, and in vitro
体内、离体和体外储库收缩和扩张的决定因素
  • 批准号:
    10579911
  • 财政年份:
    2020
  • 资助金额:
    $ 19.07万
  • 项目类别:
Determinants of reservoir contraction and expansion in vivo, ex vivo, and in vitro
体内、离体和体外储库收缩和扩张的决定因素
  • 批准号:
    10022993
  • 财政年份:
    2020
  • 资助金额:
    $ 19.07万
  • 项目类别:
Unveiling the chromosomal address of intact HIV clones to provide insights into persistence
揭示完整 HIV 克隆的染色体地址,以提供对持久性的见解
  • 批准号:
    9790462
  • 财政年份:
    2019
  • 资助金额:
    $ 19.07万
  • 项目类别:
Unveiling the chromosomal address of intact HIV clones to provide insights into persistence
揭示完整 HIV 克隆的染色体地址,以提供对持久性的见解
  • 批准号:
    9889887
  • 财政年份:
    2019
  • 资助金额:
    $ 19.07万
  • 项目类别:
A FAST Assay to Quantify HIV Reservoirs
量化 HIV 病毒库的快速检测
  • 批准号:
    9280872
  • 财政年份:
    2015
  • 资助金额:
    $ 19.07万
  • 项目类别:
A FAST Assay to Quantify HIV Reservoirs
量化 HIV 病毒库的快速检测
  • 批准号:
    8966489
  • 财政年份:
    2015
  • 资助金额:
    $ 19.07万
  • 项目类别:
An ex vivo model to predict outcomes and probe mechanism of anti-reservoir agents
预测抗储库药物结果和探讨机制的离体模型
  • 批准号:
    8930064
  • 财政年份:
    2014
  • 资助金额:
    $ 19.07万
  • 项目类别:
An ex vivo model to predict outcomes and probe mechanism of anti-reservoir agents
预测抗储库药物结果和探讨机制的离体模型
  • 批准号:
    8842406
  • 财政年份:
    2014
  • 资助金额:
    $ 19.07万
  • 项目类别:

相似海外基金

Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
  • 批准号:
    10682185
  • 财政年份:
    2023
  • 资助金额:
    $ 19.07万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    475843
  • 财政年份:
    2022
  • 资助金额:
    $ 19.07万
  • 项目类别:
    Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    474485
  • 财政年份:
    2022
  • 资助金额:
    $ 19.07万
  • 项目类别:
    Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10481430
  • 财政年份:
    2022
  • 资助金额:
    $ 19.07万
  • 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10683329
  • 财政年份:
    2022
  • 资助金额:
    $ 19.07万
  • 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
  • 批准号:
    nhmrc : 1196520
  • 财政年份:
    2021
  • 资助金额:
    $ 19.07万
  • 项目类别:
    Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10260234
  • 财政年份:
    2021
  • 资助金额:
    $ 19.07万
  • 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10548114
  • 财政年份:
    2021
  • 资助金额:
    $ 19.07万
  • 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
  • 批准号:
    10400318
  • 财政年份:
    2020
  • 资助金额:
    $ 19.07万
  • 项目类别:
Development of novel antiviral therapy targeting hepatitis B virus host restriction factor
针对乙型肝炎病毒宿主限制因子的新型抗病毒疗法的开发
  • 批准号:
    20K08371
  • 财政年份:
    2020
  • 资助金额:
    $ 19.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了